ClinicalTrials.govpublic full text
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
hiv-1 infection, hcv infection, hiv, hcv, antiretroviral therapy, hcv direct acting antiviral(s) (daa), interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1045204
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.